The Drive accelerator program, a collaborative initiative by MassBio and SCbio, has announced the selection of eleven innovative life sciences startups for its latest cohorts. With a focus on fostering breakthrough scientific advancements, this program provides essential resources and guidance to emerging companies. Since its inception in 2022, Drive has supported 59 early-stage companies—totaling 70 with the inclusion of the latest cohorts—that have collectively attracted $290 million in funding.
Cohort Focus Areas
This spring, the Drive program is divided into two distinct cohorts. One group is centered on biotechnology, while the other specializes in biomarkers and diagnostics. Notably, eight of the eleven selected startups are based in Massachusetts, underscoring the state’s position as a hub for life sciences innovation.
Eligibility Criteria
To qualify for the Drive program, startups must meet specific funding criteria. Applicants must have secured less than $1.5 million in equity-based funding prior to applying. Additionally, they must either own or have access to the intellectual property related to their science or technology, either through ownership or a licensing agreement.
Program Structure and Mentorship
The Drive program spans eight weeks, offering a comprehensive curriculum featuring six modules tailored to the life sciences industry. Esteemed industry experts, including representatives from Eli Lilly, Labcorp, and Thermo Fisher Scientific, will lead these sessions. Furthermore, participants will benefit from weekly mentorship meetings designed to function as an advisory board throughout the program’s duration. The program culminates in in-person demo days in both Boston and Charleston, South Carolina.
Exciting New Partnership
In an exciting development, MassBio has partnered with the ADA Forsyth Institute to provide additional support to program graduates. One selected startup from the Drive program will receive a sponsored lab bench for one year at the Forsyth Institute’s facility in Somerville, Massachusetts. This opportunity not only enhances the resources available to startups but also strengthens the collaborative ecosystem within the life sciences sector.
Industry Insights
Kendalle Burlin O’Connell, CEO and President of MassBio, expressed enthusiasm for the caliber of science represented in the current cohort. He noted that the selected companies reflect the future direction of drug development, including next-generation biologics, RNA medicines, and precision-targeted antibody-drug conjugates (ADCs). O’Connell emphasized the renewed attention on cardiovascular disease, which has historically been underfunded, signaling a shift towards addressing complex health challenges.
South Carolina’s Role
SCbio, the economic development organization in South Carolina, is also excited about its involvement in the Drive program. James Chappell, President and CEO of SCbio, highlighted the advantages that the state offers to diagnostic and biomarker companies. He emphasized that Drive will provide participants with access to the essential infrastructure, talent, and partnerships necessary to facilitate tangible real-world impact.
Takeaways
- Eleven life sciences startups have been selected for the latest cohorts of the Drive accelerator.
- The program focuses on biotechnology and biomarkers, with a significant representation from Massachusetts.
-
Startups must have less than $1.5 million in equity funding and appropriate intellectual property rights.
-
The eight-week program includes mentorship from industry leaders and culminates in demo days.
-
A new partnership will offer one graduate a lab bench at the ADA Forsyth Institute for enhanced research capabilities.
In conclusion, the Drive accelerator program stands as a vital resource for emerging life sciences startups, equipping them with the tools needed to innovate and thrive in a competitive landscape. As these eleven companies embark on their journey, the potential for groundbreaking advancements in healthcare and diagnostics is significant, promising a brighter future for patients and the industry alike.
Read more → www.biospace.com